New paradigms for HIV/AIDS vaccine development

Louis Picker, Scott Hansen, Jeffrey D. Lifson

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

HIV-1 and its simian counterpart SIV have been exquisitely tailored by evolution to evade host immunity. By virtue of specific adaptations that thwart individual innate or adaptive immune mechanisms, and an overall replication strategy that provides for rapid establishment of a large, systemic viral population, capable of dynamic adaptation to almost all immune selection pressures, these viruses, once established, almost invariably stay one step ahead of the host's immune system, and in the vast majority of infected individuals, replicate indefinitely. Although many vaccine approaches tested to date have been able to enhance the magnitude of the immune responses to HIV/SIV infection, most of these responses, whether cellular or humoral, have largely failed to be both effectively antiviral and targeted to prevent the emergence of fully functional escape variants. Recent advances, however, have provided strong evidence that the initial stages of infection following mucosal transmission of these viruses are more vulnerable to immune intervention, and have led to the development of vaccine strategies that elicit responses able to effectively intervene in these early stages of infection, either preventing acquisition of infection or establishing early, stringent, and durable control. Here, we place HIV/AIDS vaccine development in the context of the basic immunobiology of HIV and SIV, review the evidence for their vulnerability to immune responses immediately after mucosal transmission, and discuss how this newly recognized vulnerability might be exploited for the development of an effective HIV/AIDS vaccine.

Original languageEnglish (US)
Pages (from-to)95-111
Number of pages17
JournalAnnual Review of Medicine
Volume63
DOIs
StatePublished - 2012

Fingerprint

AIDS Vaccines
Viruses
Vaccines
Immune system
Antiviral Agents
Infection
Population Dynamics
HIV Infections
HIV-1
Immune System
Immunity
HIV
Pressure

Keywords

  • Antibody vaccines
  • HIV/SIV
  • Immune evasion
  • Nonhuman primate models
  • T cell vaccines

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

New paradigms for HIV/AIDS vaccine development. / Picker, Louis; Hansen, Scott; Lifson, Jeffrey D.

In: Annual Review of Medicine, Vol. 63, 2012, p. 95-111.

Research output: Contribution to journalArticle

@article{14bf838371164073990696dc2c4c3746,
title = "New paradigms for HIV/AIDS vaccine development",
abstract = "HIV-1 and its simian counterpart SIV have been exquisitely tailored by evolution to evade host immunity. By virtue of specific adaptations that thwart individual innate or adaptive immune mechanisms, and an overall replication strategy that provides for rapid establishment of a large, systemic viral population, capable of dynamic adaptation to almost all immune selection pressures, these viruses, once established, almost invariably stay one step ahead of the host's immune system, and in the vast majority of infected individuals, replicate indefinitely. Although many vaccine approaches tested to date have been able to enhance the magnitude of the immune responses to HIV/SIV infection, most of these responses, whether cellular or humoral, have largely failed to be both effectively antiviral and targeted to prevent the emergence of fully functional escape variants. Recent advances, however, have provided strong evidence that the initial stages of infection following mucosal transmission of these viruses are more vulnerable to immune intervention, and have led to the development of vaccine strategies that elicit responses able to effectively intervene in these early stages of infection, either preventing acquisition of infection or establishing early, stringent, and durable control. Here, we place HIV/AIDS vaccine development in the context of the basic immunobiology of HIV and SIV, review the evidence for their vulnerability to immune responses immediately after mucosal transmission, and discuss how this newly recognized vulnerability might be exploited for the development of an effective HIV/AIDS vaccine.",
keywords = "Antibody vaccines, HIV/SIV, Immune evasion, Nonhuman primate models, T cell vaccines",
author = "Louis Picker and Scott Hansen and Lifson, {Jeffrey D.}",
year = "2012",
doi = "10.1146/annurev-med-042010-085643",
language = "English (US)",
volume = "63",
pages = "95--111",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - New paradigms for HIV/AIDS vaccine development

AU - Picker, Louis

AU - Hansen, Scott

AU - Lifson, Jeffrey D.

PY - 2012

Y1 - 2012

N2 - HIV-1 and its simian counterpart SIV have been exquisitely tailored by evolution to evade host immunity. By virtue of specific adaptations that thwart individual innate or adaptive immune mechanisms, and an overall replication strategy that provides for rapid establishment of a large, systemic viral population, capable of dynamic adaptation to almost all immune selection pressures, these viruses, once established, almost invariably stay one step ahead of the host's immune system, and in the vast majority of infected individuals, replicate indefinitely. Although many vaccine approaches tested to date have been able to enhance the magnitude of the immune responses to HIV/SIV infection, most of these responses, whether cellular or humoral, have largely failed to be both effectively antiviral and targeted to prevent the emergence of fully functional escape variants. Recent advances, however, have provided strong evidence that the initial stages of infection following mucosal transmission of these viruses are more vulnerable to immune intervention, and have led to the development of vaccine strategies that elicit responses able to effectively intervene in these early stages of infection, either preventing acquisition of infection or establishing early, stringent, and durable control. Here, we place HIV/AIDS vaccine development in the context of the basic immunobiology of HIV and SIV, review the evidence for their vulnerability to immune responses immediately after mucosal transmission, and discuss how this newly recognized vulnerability might be exploited for the development of an effective HIV/AIDS vaccine.

AB - HIV-1 and its simian counterpart SIV have been exquisitely tailored by evolution to evade host immunity. By virtue of specific adaptations that thwart individual innate or adaptive immune mechanisms, and an overall replication strategy that provides for rapid establishment of a large, systemic viral population, capable of dynamic adaptation to almost all immune selection pressures, these viruses, once established, almost invariably stay one step ahead of the host's immune system, and in the vast majority of infected individuals, replicate indefinitely. Although many vaccine approaches tested to date have been able to enhance the magnitude of the immune responses to HIV/SIV infection, most of these responses, whether cellular or humoral, have largely failed to be both effectively antiviral and targeted to prevent the emergence of fully functional escape variants. Recent advances, however, have provided strong evidence that the initial stages of infection following mucosal transmission of these viruses are more vulnerable to immune intervention, and have led to the development of vaccine strategies that elicit responses able to effectively intervene in these early stages of infection, either preventing acquisition of infection or establishing early, stringent, and durable control. Here, we place HIV/AIDS vaccine development in the context of the basic immunobiology of HIV and SIV, review the evidence for their vulnerability to immune responses immediately after mucosal transmission, and discuss how this newly recognized vulnerability might be exploited for the development of an effective HIV/AIDS vaccine.

KW - Antibody vaccines

KW - HIV/SIV

KW - Immune evasion

KW - Nonhuman primate models

KW - T cell vaccines

UR - http://www.scopus.com/inward/record.url?scp=84855913888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855913888&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-042010-085643

DO - 10.1146/annurev-med-042010-085643

M3 - Article

VL - 63

SP - 95

EP - 111

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -